About This Research Desk

What Peptide Batteries is

Peptide Batteries is an independent editorial reference desk covering four research peptides — GHK-Cu, MOTS-c, retatrutide, and tirzepatide — organized around a single question: what does each do to how cells produce and use energy? MOTS-c, encoded inside mitochondrial DNA and directly tied to the AMPK fuel-sensing pathway, is the site's lead compound and its tightest fit for that frame. Tirzepatide and retatrutide are receptor agonists that regulate glucose handling and, in retatrutide's case, energy expenditure directly. GHK-Cu is included at the frame's edge — its strongest evidence is in tissue repair, not energy metabolism, and this site says so plainly rather than force the connection.

The name reflects the organizing idea, not a literal claim: none of these compounds is a battery, and this site makes no claim about supplementing or 'recharging' cellular energy in a person. It is a data-forward digest — the voice foregrounds numbers, study designs, and effect sizes, and lets the underlying evidence carry the argument rather than a marketing conclusion. Two of the four compounds, tirzepatide and, pending Phase 3 results, potentially retatrutide, are pursued as approved medicines; GHK-Cu has an approved cosmetic use; MOTS-c has no approved human use of any kind.

How it is compiled

Three principles govern this site. First, every research claim is tied to a numbered citation on the references page — peer-reviewed journal articles, clinical-trial publications, and structural or mechanistic studies, with DOIs and PubMed links where available. Second, evidence is described at the strength it was actually measured, in the population and study design that produced it: a 94-patient observational cohort is labeled as an association, not an interventional finding; a Phase 2 trial is labeled Phase 2, not treated as an approved-label result. Third, the four compound pages are cross-referenced to each other and to a single comparison page, because the same underlying questions — mechanism, evidence maturity, safety signal, regulatory status — recur across all four, just answered very differently in each case. Where a compound's fit to the site's stated cellular-energy-and-metabolism frame is loose, as with GHK-Cu, that is stated directly rather than smoothed over for consistency.

What it is not

Peptide Batteries is not a pharmacy, a clinic, a telehealth platform, or a vendor of any research chemical or medicine. It does not sell, source, or broker anything discussed on this site, has no affiliate relationship with any manufacturer or supplier, and does not recommend a dose, schedule, or route of administration for any person. Tirzepatide is available only through a licensed prescriber. Retatrutide is not approved and should be discussed only in the context of a registered clinical trial. GHK-Cu's well-documented safety record is topical and cosmetic; other uses are unapproved and unstudied in humans. MOTS-c has no approved human use at all. Readers seeking clinical guidance should consult a licensed healthcare provider; questions about citations or corrections can go to the contact page.